Nebivolol

Bezeichnung:Nebivolol

CAS-Nr118457-14-0

Englisch Name:Nebivolol

CBNumberCB92131013

SummenformelC22H25F2NO4

Molgewicht405.43

MOL-Datei118457-14-0.mol

Nebivolol physikalisch-chemischer Eigenschaften

Schmelzpunkt	155-156°C
Siedepunkt	600.5±55.0 °C(Predicted)
Dichte	1.309
storage temp.	-20°C Freezer
Löslichkeit	DMSO (Slightly), Methanol (Slightly, Heated)
pka	pKa 8.22(H2O,t =25±1,Iundefined,Ar) (Uncertain)
Aggregatzustand	Solid
Farbe	White to Off-White

Gefahreninformationscode (GHS)

Nebivolol Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden
Antihypertensive (β-blocker).
Verwenden
Nebivolol is a cardioselective beta-1 receptor blocking agent.
Definition
ChEBI: (R,S,S,S)-nebivolol is a 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] that has (1S,1'S,2R,2'S)-configuration. It is a conjugate base of a (R,S,S,S)-nebivolol(1+). It is an enantiomer of a (S,R,R,R)-nebivolol.
Clinical Use
Beta-adrenoceptor blocker:
Essential hypertension
Adjunct in heart failure
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: NSAIDs antagonise hypotensive effect.
Anti-arrhythmics: increased risk of myocardial depression and bradycardia; increased risk of bradycardia, myocardial depression and AV block with amiodarone; increased risk of myocardial depression and bradycardia with flecainide.
Antidepressants: enhanced hypotensive effect with MAOIs.
Antihypertensives; enhanced hypotensive effect; increased risk of withdrawal hypertension with clonidine; increased risk of first dose hypotensive effect with post-synaptic alpha-blockers such as prazosin.
Antimalarials: increased risk of bradycardia with mefloquine.
Antipsychotics enhanced hypotensive effect with phenothiazines.
Calcium-channel blockers: increased risk of bradycardia and AV block with diltiazem; hypotension and heart failure possible with nifedipine and nisoldipine; asystole, severe hypotension and heart failure with verapamil.
Cytotoxics: possible increased risk of bradycardia with crizotinib.
Diuretics: enhanced hypotensive effect.
Fingolimod: possibly increased risk of bradycardia. Moxisylyte: possible severe postural hypotension.
Sympathomimetics: severe hypertension with adrenaline and noradrenaline and possibly with dobutamine.
Stoffwechsel
Nebivolol is extensively metabolised in the liver by acyclic and aromatic hydroxylation, N-dealkylation, and glucuronidation. Hydroxylation is by cytochrome P450 isoenzyme CYP2D6, partly to active hydroxy-metabolites. It is excreted in the urine and faeces, almost entirely as metabolites.

Nebivolol Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Send Inquriy